Recently approved for moderate to severe psoriasis, the oral IL-23 inhibitor icotrokinra has demonstrated strong efficacy for high-impact disease sites.
Medscape Medical News
Source link
Recently approved for moderate to severe psoriasis, the oral IL-23 inhibitor icotrokinra has demonstrated strong efficacy for high-impact disease sites.
Medscape Medical News
Source link